Switching from Wegovy or Ozempic/ Semaglutide to Mounjaro (trizepatide): A Safe Transition Guide | Karespot

Semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) are both once-weekly injectables, but they are not the same drug. Semaglutide activates only the GLP-1 receptor; tirzepatide activates both GIP and GLP-1 receptors, a dual action that in head-to-head data produces greater average weight loss. In the landmark SURMOUNT-5 trial (New England Journal of Medicine, 2025), patients on tirzepatide lost an average of 20.2% of body weight over 72 weeks versus 13.7% on semaglutide. More tirzepatide patients also reached the 10%, 15%, 20% and 25% weight-loss milestones. [1]

This does not mean Mounjaro is automatically better for everyone. Treatment response, gastrointestinal tolerance, access, cost, and co-existing conditions all factor into the right choice. [2] What it does mean is that a switch can make clinical sense, and that it requires a personalised plan, not a direct dose conversion.

Before recommending any change in therapy, Karespot's MBBS + MD Internal Medicine specialists conduct a full review of treatment history, weight-loss progress, metabolic health, and medication tolerance. Related background in the Kare Hub: Wegovy vs Ozempic: What Is the Difference? [5], Semaglutide Guide: Weight Loss, Side Effects and Safe Use [9], and All You Need to Know About Semaglutide [17].

Before taking any medical guidance at face value, it is reasonable to ask who is behind it. Here is a transparent answer.

All Karespot clinical content is developed with input from registered doctors holding MBBS + MD (Internal Medicine) qualifications, the same doctors who issue your prescription. Both prescribers are individually named, MCI-registered, and actively practise metabolic medicine. They are available for online consultations across India via karespot.in/products/doctor-consultation-internal-medicine.

Unlike services that prescribe and step away, Karespot pairs every GLP-1 patient with a registered dietician, a clinical psychologist, and a lifestyle health coach. The STEP-3 trial (JAMA, 2021) demonstrated that semaglutide combined with intensive behavioural therapy produced meaningfully greater weight loss than medication alone. [3] Without nutritional and resistance-exercise support, up to 40% of GLP-1 weight loss can come from lean muscle rather than fat [4], a risk Karespot's programme is specifically designed to mitigate.

Yes, many patients can safely transition from Wegovy or Ozempic (semaglutide) to Mounjaro (tirzepatide) under medical supervision. Both medications support weight management through overlapping but non-identical pathways [5], so a personalised transition plan is necessary to maintain effectiveness and minimise side effects.

Mounjaro doses are not directly interchangeable with semaglutide doses. Your current dose, treatment duration, tolerance, and overall health determine the most appropriate tirzepatide starting dose. [6] A gradual transition reduces the risk of nausea, vomiting, diarrhoea, and abdominal discomfort. For a full breakdown of Mounjaro side effects and how to manage them, see: What Are the Side Effects of Mounjaro and How to Manage Them? [11]

Patients should not assume they can begin tirzepatide at a high dose because they previously used semaglutide. In SURMOUNT-5, GI-related treatment discontinuation was only 2.7% for tirzepatide versus 5.6% for semaglutide [1], but those low rates were achieved because all participants followed the recommended escalation protocol. A slower start does not mean slower long-term results; establishing good tolerance early is key to sustainable outcomes.

The SURMOUNT-5 head-to-head trial, the first direct, randomised comparison of these medications, found tirzepatide superior for body-weight and waist-circumference reduction over 72 weeks. [1] A similar tirzepatide advantage was seen in SURMOUNT-1 (NEJM, 2022), reporting up to 20.9% average weight loss at the highest dose. [7] For a detailed side-by-side comparison of the semaglutide brands specifically, see: Wegovy vs Ozempic: What Is the Difference? [5]

Neither medication is universally superior for every individual. Suitability depends on side-effect tolerance, medical history, goals, and access. Karespot's doctors weigh all these factors during your consultation.

"Food noise" refers to the constant, intrusive preoccupation with food and cravings that many patients with obesity experience. It is one of the most clinically significant benefits of GLP-1 therapy. A 2025 EASD-presented INFORM survey found a 46% decline in patients experiencing constant food thoughts after starting semaglutide, with those reporting negative life impact falling from 60% to 20%.

Tirzepatide's additional GIP receptor activity may produce an even stronger reduction in food noise for some patients. A peer-reviewed conceptual model of food-cue reactivity (PMC, 2023) proposed that GLP-1 receptor agonists reduce the "seek food now" signal by acting on the hypothalamus, mesolimbic system, and hindbrain simultaneously [8], distinct from simple calorie restriction. This neurological quieting of food thoughts is why many patients describe the experience as transformational.

This is explored in depth in the Kare Hub guide: Silencing Food Noise: How Medical Weight Loss Treatment Can Help [10]

Transitioning is more than changing weekly injections. Because semaglutide and tirzepatide have different active ingredients and dosing schedules, the switch must be carefully planned. [6] Karespot's doctors structure this as a four-phase process.

Both medications are effective. The decision to switch is typically driven by a combination of clinical, practical, and personal factors. [6]

Not necessarily. Many patients achieve excellent, sustained results with semaglutide and have no clinical reason to change. The decision requires thorough evaluation of benefits, risks, treatment response, and personal circumstances.

Semaglutide and tirzepatide do not cause physical dependence and are not associated with traditional withdrawal. However, if a gap exists between stopping one medication and starting the other, some individuals may notice increased hunger, stronger cravings, or reduced fullness as the previous medication's appetite-regulating effect diminishes before the new treatment becomes established.

Related Kare Hub reading: Silencing Food Noise: How Medical Weight Loss Treatment Can Help [10]  ·  What Is Water Weight? Myths, Facts and How to Lose It [15]  ·  How to Calculate Your BMR for Weight Loss [14]

Medication is a powerful start, but clinical evidence is clear: patients who receive holistic support alongside GLP-1 therapy achieve better, more durable outcomes. [3] Without nutritional and exercise support, up to 40% of weight lost on GLP-1 medication can come from lean muscle rather than fat [4], slowing metabolism and increasing the risk of regain when treatment ends. Karespot's programme directly addresses this.

Every Karespot patient receives doctor-led medical supervision (MBBS + MD, involved throughout), registered dietician coaching (tracking intake and refining nutrition), psychologist support (addressing emotional drivers of weight gain and food noise), and lifestyle health coaching (building habits that outlast the medication).

All articles below are published on the Karespot Kare Hub and written with clinical input from our MBBS + MD Internal Medicine team.